Veterans Affairs Pharmacist Heart Failure Medication Titration Project 1
- Conditions
- Heart Failure
- Interventions
- Other: Audit and Feedback EmailsOther: Educational ResourcesOther: Patient Specific Targets
- Registration Number
- NCT06099808
- Lead Sponsor
- Stanford University
- Brief Summary
This is a randomized quality improvement project to evaluate the impact of an audit and feedback intervention to motivate pharmacists to provide heart failure (HF) medication management to patients in the Veterans Health Administration (VHA) Sierra Pacific region (VISN 21). The results of this project could provide guidance for how to successfully scale a pharmacist-based HF remote management program in the VHA more broadly.
Pharmacists providing clinical care as part of Patient Aligned Care Team (PACT) within VHA VISN 21 will be included. Pharmacists will be randomized to one of 3 arms in a 1:1:2 ratio: (1) monthly audit and feedback of HF medication titration activities (AF) vs. (2) educational resources and monthly notification of HF medication titration actions in addition to a list of potential patients for HF optimization (AF+) vs. (3) usual care without audit and feedback (UC). Pharmacists across all three arms will be given access to shared educational resources on HF pharmacist care and educational webinars. Six months after the intervention, rates of pharmacist HF medication titration encounters will be compared among the 3 groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 110
- Clinical pharmacists in the Veterans Health Administration that provide Patient Aligned Care Team (PACT) care in VA Sierra Pacific Network (VISN 21)
- Excluded per pharmacist supervisor decision
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Audit and Feedback (AF) Audit and Feedback Emails Pharmacists randomized to audit and feedback will receive a monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. The audit and feedback email will also contain rates of medical therapy and percentage of patients on \>50% of the target dose of medical therapy stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard. Pharmacists in AF will also receive invitations to monthly educational sessions and access to shared resources on HF medication management. Audit and Feedback (AF) Educational Resources Pharmacists randomized to audit and feedback will receive a monthly email containing information including their total medication titration encounters over a 3 month period, as well as the site and VISN level for comparison. The audit and feedback email will also contain rates of medical therapy and percentage of patients on \>50% of the target dose of medical therapy stratified by site, VISN and national. This data will be obtained from VHA national HF dashboard. Pharmacists in AF will also receive invitations to monthly educational sessions and access to shared resources on HF medication management. Audit and Feedback with Patient Specific Targets (AF+) Audit and Feedback Emails Pharmacists randomized to the AF+ group will receive the audit and feedback intervention described above with the addition of a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. These patients will be identified using the VHA national HF dashboard. Audit and Feedback with Patient Specific Targets (AF+) Educational Resources Pharmacists randomized to the AF+ group will receive the audit and feedback intervention described above with the addition of a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. These patients will be identified using the VHA national HF dashboard. Audit and Feedback with Patient Specific Targets (AF+) Patient Specific Targets Pharmacists randomized to the AF+ group will receive the audit and feedback intervention described above with the addition of a list of 5-7 HF patients who are potentially eligible for pharmacist HF medication titration. These patients will be identified using the VHA national HF dashboard. Usual Care Educational Resources Pharmacists randomized to the usual care arm will have access to monthly educational sessions and to shared resources on HF medication management. They will receive no additional feedback.
- Primary Outcome Measures
Name Time Method Number of monthly heart failure medication adjustment encounters 2 months post-randomization to 6 months post-randomization Encounters in which pharmacist adjusted heart failure medications
- Secondary Outcome Measures
Name Time Method Beta-blocker therapy At 6 months post randomization Percentage of patients with heart failure with reduced ejection fraction in each pharmacist panel that are treated with beta-blocker therapy
Number of new patients with pharmacist HF management Within 6 months post-randomization For each pharmacist, will calculate the number of patients with heart failure in their panel that receive care from pharmacist that were not receiving care prior to randomization
Guideline medical therapy score At 6 months post randomization Composite score of heart failure medical therapy among patients with heart failure for patients within each pharmacists panel
Renin-angiotensin system inhibitor (RASI) therapy At 6 months post randomization Percentage of patients with heart failure with reduced ejection fraction in each pharmacist panel that are treated with RASI therapy
Percentage of heart failure patients with medication management by pharmacist Within 6 months post-randomization For each pharmacist, will calculate the percentage of patients with heart failure in their panel that receive medication adjustments from pharmacist
Angiotensin receptor neprilysin inhibitor (ARNI) therapy At 6 months post randomization Percentage of patients with heart failure with reduced ejection fraction in each pharmacist panel that are treated with ARNI therapy
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) therapy At 6 months post randomization Percentage of patients with heart failure in each pharmacist panel that are treated with SGLT2i therapy
Mineralocorticoid receptor antagonist (MRA) therapy At 6 months post randomization Percentage of patients with heart failure in each pharmacist panel that are treated with MRA therapy
Trial Locations
- Locations (1)
Palo Alto Veteran's Affairs Hospital
🇺🇸Palo Alto, California, United States